Study S000229

Effect of AC 2993 (Synthetic Exendin-4) - Administered Alone or in Combination With Daclizumab - on Islet Function in Patients With Type I Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00064714
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: COMPLETED
Enrollment: 47
Start: 2003-07
Primary completion: 2008-03
Lead sponsor: AstraZeneca
Conditions: Diabetes Mellitus
Interventions: DRUG:AC2993 (exenatide); DRUG:daclizumab (immunosuppressive)
Results posted: FALSE
Secondary identifiers: OTHER:03-DK-0245

Registered primary outcomes

Change in basal C-peptide level [baseline and 6 months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025808	Exenatide Improves HDL Particle Counts and Size Distribution in Patients With Long-standing Type 1 Diabetes. Gourgari EA, Diabetes care	2017	Randomized trial	PMID 28515131 DOI	cites ClinicalTrials.gov:NCT00064714
R0027271	Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Rother KI, Diabetes care	2009	Randomized trial	PMID 19808924 DOI	cites ClinicalTrials.gov:NCT00064714; registry reference DERIVED:19808924